145 related articles for article (PubMed ID: 32380831)
1.
Bruzzone C; Loizaga-Iriarte A; Sánchez-Mosquera P; Gil-Redondo R; Astobiza I; Diercks T; Cortazar AR; Ugalde-Olano A; Schäfer H; Blanco FJ; Unda M; Cannet C; Spraul M; Mato JM; Embade N; Carracedo A; Millet O
J Proteome Res; 2020 Jun; 19(6):2419-2428. PubMed ID: 32380831
[TBL] [Abstract][Full Text] [Related]
2. NMR spectroscopy of filtered serum of prostate cancer: A new frontier in metabolomics.
Kumar D; Gupta A; Mandhani A; Sankhwar SN
Prostate; 2016 Sep; 76(12):1106-19. PubMed ID: 27197810
[TBL] [Abstract][Full Text] [Related]
3. Distinct Metabolic Signatures of Hormone-Sensitive and Castration-Resistant Prostate Cancer Revealed by a
Zheng H; Zhu Y; Shao X; Cai A; Dong B; Xue W; Gao H
J Proteome Res; 2020 Sep; 19(9):3741-3749. PubMed ID: 32702989
[TBL] [Abstract][Full Text] [Related]
4. NMR-Based Prostate Cancer Metabolomics.
Euceda LR; Andersen MK; Tessem MB; Moestue SA; Grinde MT; Bathen TF
Methods Mol Biol; 2018; 1786():237-257. PubMed ID: 29786797
[TBL] [Abstract][Full Text] [Related]
5. Identification of characteristic metabolic panels for different stages of prostate cancer by
Zhang X; Xia B; Zheng H; Ning J; Zhu Y; Shao X; Liu B; Dong B; Gao H
J Transl Med; 2022 Jun; 20(1):275. PubMed ID: 35715864
[TBL] [Abstract][Full Text] [Related]
6. NMR-based metabolomics analysis identifies discriminatory metabolic disturbances in tissue and biofluid samples for progressive prostate cancer.
Zheng H; Dong B; Ning J; Shao X; Zhao L; Jiang Q; Ji H; Cai A; Xue W; Gao H
Clin Chim Acta; 2020 Feb; 501():241-251. PubMed ID: 31758937
[TBL] [Abstract][Full Text] [Related]
7. Comprehensive metabolomics analysis of prostate cancer tissue in relation to tumor aggressiveness and TMPRSS2-ERG fusion status.
Dudka I; Thysell E; Lundquist K; Antti H; Iglesias-Gato D; Flores-Morales A; Bergh A; Wikström P; Gröbner G
BMC Cancer; 2020 May; 20(1):437. PubMed ID: 32423389
[TBL] [Abstract][Full Text] [Related]
8. GC-MS-based metabolomics reveals new biomarkers to assist the differentiation of prostate cancer and benign prostatic hyperplasia.
Wang W; He Z; Kong Y; Liu Z; Gong L
Clin Chim Acta; 2021 Aug; 519():10-17. PubMed ID: 33831421
[TBL] [Abstract][Full Text] [Related]
9. The effect of sampling procedures and day-to-day variations in metabolomics studies of biofluids.
Giskeødegård GF; Andreassen T; Bertilsson H; Tessem MB; Bathen TF
Anal Chim Acta; 2019 Nov; 1081():93-102. PubMed ID: 31446969
[TBL] [Abstract][Full Text] [Related]
10. Noninvasive urine metabolomics of prostate cancer and its therapeutic approaches: a current scenario and future perspective.
Kumar D; Nath K; Lal H; Gupta A
Expert Rev Proteomics; 2021 Nov; 18(11):995-1008. PubMed ID: 34821179
[TBL] [Abstract][Full Text] [Related]
11. Metabolomics profiling and pathway analysis of human plasma and urine reveal further insights into the multifactorial nature of coronary artery disease.
Amin AM; Mostafa H; Arif NH; Abdul Kader MAS; Kah Hay Y
Clin Chim Acta; 2019 Jun; 493():112-122. PubMed ID: 30826371
[TBL] [Abstract][Full Text] [Related]
12. Altered staining patterns and expression level of Engrailed-2 in benign prostatic hyperplasia and prostate Cancer predict prostatic disease progression.
Li Q; Shi Y; Sa R; Hao J; Hu J; Xiao M; Wang C; Yan L; Qiao B; Chen G
BMC Cancer; 2020 Jun; 20(1):555. PubMed ID: 32539763
[TBL] [Abstract][Full Text] [Related]
13. NMR-based metabolomics studies of human prostate cancer tissue.
Lima AR; Pinto J; Bastos ML; Carvalho M; Guedes de Pinho P
Metabolomics; 2018 Jun; 14(7):88. PubMed ID: 30830350
[TBL] [Abstract][Full Text] [Related]
14. Novel Metabolic Signatures of Prostate Cancer Revealed by
Yang B; Zhang C; Cheng S; Li G; Griebel J; Neuhaus J
Diagnostics (Basel); 2021 Jan; 11(2):. PubMed ID: 33498542
[TBL] [Abstract][Full Text] [Related]
15. Potential of nuclear magnetic resonance metabolomics in the study of prostate cancer.
Reddy RR; Jagannathan NR
Indian J Urol; 2022; 38(2):99-109. PubMed ID: 35400867
[TBL] [Abstract][Full Text] [Related]
16. Non-invasive urinary metabolomic profiling discriminates prostate cancer from benign prostatic hyperplasia.
Pérez-Rambla C; Puchades-Carrasco L; García-Flores M; Rubio-Briones J; López-Guerrero JA; Pineda-Lucena A
Metabolomics; 2017; 13(5):52. PubMed ID: 28804274
[TBL] [Abstract][Full Text] [Related]
17. Relevance of emerging metabolomics-based biomarkers of prostate cancer: a systematic review.
Bansal N; Kumar M; Sankhwar SN; Gupta A
Expert Rev Mol Med; 2022 Jun; 24():e25. PubMed ID: 35730322
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of prostate cancer tissue metabolomics: would clinics utilise it for diagnosis?
Bansal N; Kumar M; Sankhwar SN; Gupta A
Expert Rev Mol Med; 2023 Aug; 25():e26. PubMed ID: 37548191
[TBL] [Abstract][Full Text] [Related]
19. In vivo proton magnetic resonance spectroscopy of diseased prostate: spectroscopic features of malignant versus benign pathology.
García-Segura JM; Sánchez-Chapado M; Ibarburen C; Viaño J; Angulo JC; González J; Rodríguez-Vallejo JM
Magn Reson Imaging; 1999 Jun; 17(5):755-65. PubMed ID: 10372529
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
